GDTC NASDAQ
CytoMed Therapeutics Limited
1W: -7.8%
1M: +0.0%
3M: -9.3%
YTD: -36.7%
1Y: -56.2%
3Y: -74.2%
$0.92
+0.02 (+2.23%)
Weekly Expected Move ±12.4%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$52K
-82.1% ▼
Gross Profit
$52K
-86.3% ▼
Operating Income
-$3M
+17.9% ▲
Net Income
-$2M
+39.9% ▲
EPS (Diluted)
$-0.16
+44.8% ▲
EBITDA
-$2M
+39.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $45K | $84K | $0 | $291K | $52K |
| YoY Growth | +0.0% | +87.4% | -100.0% | +0.0% | -82.1% |
| Cost of Revenue | $3K | $3K | $81K | $3K | $23K |
| Gross Profit | $41K | $82K | -$81K | $382K | $52K |
| Gross Margin | 92.2% | 96.9% | — | 131.4% | 100.7% |
| R&D Expenses | $784K | $806K | $1M | $1M | $1M |
| SG&A Expenses | $117K | $435K | $443K | $371K | $1M |
| Operating Expenses | $892K | $937K | $2M | $2M | $2M |
| Operating Income | -$1M | -$1M | -$2M | -$3M | -$3M |
| Operating Margin | -2233.0% | -1661.4% | — | -1101.0% | -5049.8% |
| Interest Expense | $80K | $88K | $91K | $38K | $15K |
| Income Before Tax | -$1M | -$2M | -$2M | -$3M | -$2M |
| Tax Expense | $0 | $0 | $1K | $486 | $0 |
| Net Income | -$1M | -$2M | -$2M | -$3M | -$2M |
| Net Margin | -3266.1% | -1822.3% | — | -1077.8% | -3621.1% |
| EPS (Diluted) | $-0.25 | $-0.22 | $-0.30 | $-0.29 | $-0.16 |
| EBITDA | -$776K | -$1M | -$1M | -$3M | -$2M |
| Shares Outstanding | 6M | 7M | 8M | 11M | 12M |